Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases
- 1 January 2018
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 24 (1) , 18-29
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health, NIH (K01 AG055694, RF1 AG056151)
- Cure Alzheimer’s Fund
This publication has 104 references indexed in Scilit:
- Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body DementiaJournal of Alzheimer’s Disease, 2017
- Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signalingNature Medicine, 2015
- Regulation of neuronal communication by G protein‐coupled receptorsFEBS Letters, 2015
- G protein-coupled receptors as therapeutic targets for multiple sclerosisCell Research, 2012
- Enhancement of proteasome activity by a small-molecule inhibitor of USP14Nature, 2010
- Disease-Associated Prion Protein Oligomers Inhibit the 26S ProteasomeMolecular Cell, 2007
- The effects of chronic phosphodiesterase-5 inhibitor use on different organ systemsInternational Journal Of Impotence Research, 2006
- Ubiquitin and the synapseNature Reviews Neuroscience, 2002
- Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in BrainScience, 1997
- Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairmentAnnals of Neurology, 1991